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Abstract
Background: A combination of artesunate (AS) plus sulphadoxine/pyrimethamine (SP) as first-line
and artemether-lumefantrine (AL) as second-line treatment are currently recommended against
uncomplicated P. falciparum infection in Sudan. However, there is limited information on the
efficacy of ACTs in the country and only one report of PCR-corrected results for AS/SP only.
Methods: The WHO protocol for the assessment of antimalarial drug efficacy for the treatment
of uncomplicated falciparum malaria was employed. Artesunate plus sulphadoxine/pyrimethamine
(AS/SP) was compared to artemether-lumefantrine (AL) in a 28-day follow up. Samples that were
classified as early treatment failure (ETF), late treatment failure (LCF) or late parasitological failure
(LPF) were genotyped for msp-1 and msp-2 genes to differentiate recrudescence from reinfection.
Results: A total of 178 patients were screened and 160 met the enrolment criteria and were
recruited to the study of which 157 (98.1%) completed the follow up and had an analysed treatment
outcome. On the AS/SP arm, three (0.038%) patients were lost during the follow-up, two on day
1 and one on day 7, and 77 (96.3) completed the study, while all 80 (100%) patients completed the
follow up in the AL arm. In the per protocol analysis for AS/SP the treatment outcome for patients
who completed the follow-up were as follows: adequate clinical and parasitological response
(ACPR); 84.4% ETF; 1.3%, LCF; 3.9%, (LPF); 10.4%. For the AL arm the out come was as follows,
ACPR; 90%, ETF; 0%, LCF; 6.3% and LPF; 3.8%. However, when PCR-corrected, 6.5% (5/77) of
patients treated with AS/SP maintained parasites from their primary infection, while (7/80) in the
AL group maintained their initial parasite genotype. Therefore, PCR-corrected efficacy was 93.5%
in the AS/SP treated group and for AL it was 91.3%.
Conclusion: Both AS/SP and AL are highly effective for the treatment of uncomplicated falciparum
malaria in eastern Sudan. However, AS/SP appears to have a slightly higher efficacy than AL, this
may be due to patient compliance with the repeated dose rather than drug efficacy.
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Background
Malaria remains one of the major public health problems
in Africa. It is estimated that 7.5 to 10 million cases of
malaria occur in Sudan every year [1]. Control mainly
depends on treating symptomatic cases with available
chemotherapeutics. The WHO recommends artemisinin-
based combination therapies (ACT) for treatment of
uncomplicated malaria. Due to decreased sensitivity of
Plasmodium falciparum to chloroquine [2] and sulphadox-
ine/pyrimethamine (SP) [3,4], the National Malaria Con-
trol Programme (NMCP) of Sudan has recently adopted
ACT for treatment of uncomplicated malaria [5]. Artemisi-
nins are known to have a marked effect on reducing para-
sitaemia even when multi-drug resistant parasites are
present. However, their short half-life warrants that a sec-
ond drug with long half-life is administered concurrently.
The current treatment protocol for uncomplicated falci-
parum malaria in Sudan is artesunate plus sulphadoxine/
pyrimethamine, as first-line and artemether-lumefantrine
as second-line of treatment [5]. There have been few stud-
ies on the efficacy of AS/SP [6-9] and only one published
report on the efficacy of AL in Sudan [8]. Although these
studies have reported high efficacy to both combinations,
ranging from 99.8% to 100%, they did not show whether
the small proportion of treatment failures was due to a
recrudescence of existing parasites or acquisition of a new
infection, except for one recent study which reported the
PCR-corrected efficacy of AS/SP [9]. It was, therefore,
decided to closely monitor patients for 28 days after treat-
ment with AS/SP or AL, and the results were genotyped to
indicate recrudescence versus new infections.
Methods
Sample size
A trial with 80 subjects in each arm would have at least
80% power (using a significance level of 0.10) to detect a
difference between the two combinations if the failure
rate detected after treatment is 20% in the AS/SP arm
(based on the reported failure of SP of approximately 15
– 20% in Sudan) and 5% in AL arm, allowing for 10% loss
to follow-up.
Study population and field survey
The study was carried out in three villages in eastern
Sudan, southwest of Gedarif town (Abunaja Juama, Abu-
naja Bargo and Asar). A community-based survey was
conducted during the transmission seasons (October to
December) of 2004 and 2005 to identify symptomatic
patients that were microscopically diagnosed with mono
infection of P. falciparum. Patients that satisfied the enrol-
ment criteria according to the WHO protocol for the
assessment and monitoring of antimalarial drug efficacy
for the treatment of uncomplicated falciparum malaria
[10] were recruited after they provided written informed
consent to participate. However, due to the low endemic-
ity of malaria in this area all age groups were recruited.
Patients were randomly allocated to receive either AS/SP
or AL by a simple random technique of a hat draw. Preg-
nant women were not enrolled as per the national proto-
col for uncomplicated malaria recommendations.
Sample collection
Finger prick blood samples were collected and thick and
thin smears were prepared on a patient's first attendance.
When the patient was enrolled to the study, a finger prick
sample was collected on days 0, 1, 2, 3, 7, 14, 21, and 28
on a glass slide and a parallel drop of blood was collected
on filter paper. The filter paper was air-dried and stored in
self-sealing plastic bags for molecular analysis.
Microscopic diagnosis
Thick and thin blood smears were stained with Giemsas'
stain for ten minutes. The slides were read by two inde-
pendent experienced microscopists. Parasite count was
performed by counting asexual parasites against 200
white blood cells (WBC), and parasite density calculated
assuming an average of 6,000 WBC in the population. Ten
percent of the slides were read by a third microscopist in
Khartoum for quality control. In case of disagreement the
majority result was taken.
Treatment and follow up schedule
Each patient was allocated randomly to either AS/SP or
AL, treatment was administered under supervision for the
AS/SP group, while only one dose of the AL was super-
vised and the second dose was given to the patient for self-
administration. Patients were asked to return to the clinic
on days 1, 2, 3, 7, 14, 21, and 28 or whenever they did not
feel well. When a patient failed to come to the clinic on
any scheduled day, a member of the team visited the
home, gave them the dose and obtained the sample unless
the patient was not found or refused to give the sample.
Those who refused to give their sample (withdrawn) or
missed more than one day of follow-up were excluded
from the analysis.
Patients, who were positive by microscopy and refused to
participate in the study or did not meet the enrolment cri-
teria, were provided with AS/SP for self-administration
whereas pregnant women were referred to Gedarif Teach-
ing Hospital as recommended by the national protocol.
In vivo analysis
A per protocol analysis was performed employing the
WHO excel sheet [11].
Samples that were positive by microscopy on any of the
follow-up days were classified as early treatment failure
(ETF), late parasitological failure (LPF), or late clinical
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failure (LCF). Adequate clinical and parasitological
response (ACPR) was defined as complete absence of
microscopically detectable parasitaemia during the fol-
low-up period, according to the protocol [10].
Molecular analysis
Samples that were classified as ETF, LCF or LPF were gen-
otyped by PCR as previously described for msp-1 [12] and
msp-2 [13,14] on day 0, 1, 2, 3 and failure (day 7 to 28) to
differentiate recrudescence from reinfection. Unpublished
observations indicate the necessity of day 0 to day 3 sam-
pling to accurately identify recrudescence from re-infec-
tion.
Ethical considerations
The study was reviewed and ethical clearance was
obtained from the National Ethical Committee, Federal
Ministry of Health, Sudan. Individual written informed
consent was obtained from all participants or their legal
guardians.
Results
In vivo outcome
178 patients were screened and 160 patients were
enrolled and 157 completed the follow-up and had an
analysable outcome. Of these, 77 patients were in the AS/
SP arm and 80 were in the AL arm. Table 1 shows the
description of the study population that successfully com-
pleted the follow-up.
A total of 77 patients completed the follow-up on the AS/
SP group and 84.4% had an adequate clinical and parasi-
tological response (ACPR). Of the 80 patients that
received AL and completed the follow-up, 90% had suc-
cessfully cleared their parasitaemia by day 28. Table 2
summarizes the outcome of treatments in each group.
Genotyping
Of the 157 patients diagnosed with P. falciparum on day 0
and who completed the follow up twenty patients had
microscopically detectable parasitaemia on at least one
day of the follow-up. Of these twelve received AS/SP and
the remaining eight received AL. These samples were gen-
otyped for msp-1 and msp-2 genes.
In the AS/SP group, five patients (41.7 %) showed differ-
ent allelic forms and were classified as reinfection, while
seven (58.3) retained the same allelic pattern and were
classified as recrudescence of parasites. Only one (1.25%)
patient showed a different genotype in the AL group and
the remaining 7 (87.5%) retained their initial parasite
genotype. Hence, PCR-corrected efficacy was 93.5% and
91.3% for AS/SP and AL, respectively.
Discussion
Artemisinin derivatives are highly effective antimalarial
compounds against different stages of Plasmodium devel-
opment [15]. In order to prolong the efficacy of these
drugs, it is recommended that they should only be used in
combination with another effective drug that has a longer
Table 2: In vivo outcome of AS/SP and AL
Prevalence n (%)
AS/SP AL
ETF 1 (1.3) 0 (0)
LCF 3 (3.9) 5 (6.3)
LPF 8 (10.4) 3 (3.8)
ACPR 65 (84.4) 72 (90)
Total analysed 77 (96.3) 80 (100)
WITH 3 (3.7) 0 (0)
TOTAL 80 80
ETF; early treatment failure; LCF: late clinical failure; LPF: late parasitological failure; ACPR: adequate clinical and parasitological response; WITH: 
withdrawal; as analysed by the WHO worksheet.
Table 1: Description of study population receiving AS/SP or AL treatment
Drug
AS/SP AL
Age_years Mean (95% CI) 17.88 (14.48 – 21.28) 18.45 (14.84 – 22.06)
Temperature Day 0 Mean (95% CI) 37.46 (37.46 – 37.70) 37.59 (37.35 – 37.83)
Sex Female n (%) 39 (48.8) 47(58.8)
Male n (%) 41 (51.2) 33(41.2)
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Map of SudanFigure 1
Map of Sudan. Red circles indicate the town locations reported in previous studies (Ed Damazin, Kosti, Kassala and Malakal) 
compared to this study (Gedaref). Other areas except Kassala are on the Nile River bank and have irrigated agricultural activi-
ties.
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half-life. This current consensus of antimalarial therapy
has led to the adoption of ACT in Sudan where chloro-
quine (CQ) has reached high levels of treatment failure
[2,3,16].
In Sudan, the current recommendation for uncomplicated
malaria are AS/SP and AL as first and second-line treat-
ment, respectively [5] with 100% efficacy in Damazin,
Kosti, Malakal and New Halfa [6-9,17] and 99.3% in Kas-
sala [7].
In the present study, PCR-corrected results showed effi-
cacy of AS/SP to be 93.5% in the Gedarif area. Although
this is lower than the reports mentioned above, it is not
surprising. Samples analysed in the present study were
collected in 2004 and 2005, a time coinciding with
increased use of SP mono-therapy due to the failure of
CQ, which may have lead to increased levels of resistance
to this drug. Although there is no recent report of SP clin-
ical efficacy in our study area, alleles associated with SP
failure have been reported to be increasing gradually. Tri-
ple mutants on dhfr-108Asn, dhfr-59 and dhps-540Leu
have rapidly increased in this area between 1993 to 1999
[18]. Data from this area shows that these alleles have
reached higher levels in 2003 and 2004 just before the
implementation of ACTs [19].
The partial failure of AL (8.9%) may be explained by inab-
sorption of lumefantrine due to low fat diet a situation
that may be common in rural areas. In addition, recrudes-
cence of AL-treated individuals has been reported in stud-
ies from other parts of the world [20-22].
The present study has provided detailed PCR-corrected
results of AS/SP and AL efficacy in eastern Sudan.
Although the results may seem in disagreement with oth-
ers, this is mainly due to the different transmission inten-
sities in Sudan. In irrigated areas where there is perennial
transmission such as Damazin, New Halfa, Malakal and
Kosti (Figure 1) there is a higher chance of recombination
within the parasite population. However, in areas of low
seasonal transmission such as the Gedarif area, recombi-
nation may be much lower leading to the lower multiplic-
ity of infection (MOI). This may have led to
underestimation of reinfection in our study. In addition
parasite tolerance to the lumefantrine component persist-
ing at a low levels than required to kill parasites that have
caused new infection may also contribute to high levels of
failure [23].
Conclusion
Artemisinin-based combination therapies are considered
to be highly effective antimalarials available in endemic
countries. Artemisinin is highly effective in eliminating
parasitaemia, however the partner drug is an important
component in prolonging the usefulness of this combina-
tion. The results shown here call for continuous monitor-
ing of the efficacy of ACT in eastern Sudan.
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